Substitute for	or form 1449A/PTO)			COMPLETE IF KNOWN	
INFO	RMATIO	N DISC	CLOSURE	Application Number	10/560,290	
4ACT AT	EMENT I	D37 A 10 E	PE	Filing Date	December 12, 2005	
- ^3			/	Rirst Named Inventor	H. Sings et al.	
√ gyun ₩			MAR O. 8 SUUR	B roup Art Unit		
Juse	e as many she	eets as ne	cessary)	Examiner Name		
BARCET	1	of	PRADENT	Attorney Docket Number	21278P	······
	INFO	INFORMATIO	ATEMENT BY APP	INFORMATION DISCLOSURE ANT ATEMENT BY APPLICANT 40 Right 10 9 2008 Suse as many sheets as necessary)	INFORMATION DISCLOSURE Application Number Filing Date First Named Inventor Fighth Filing Date First Named Inventor Fighth Fighth	INFORMATION DISCLOSURE Application Number 10/560,290 Filing Date December 12, 2005 First Named Inventor H. Sings et al. Place as many sheets as necessary) Fixaminer Name

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document Number			Date of Publication of Cited Document MM-DD-YYYY			
GW		6166037		Budhu et al.	12/26/2000			
-								

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Docu Office Number	ment Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
KW	_	WO 02/068388		Merck & Co., Inc.	09/06/2002		
		WO 02/068387		Merck & Co., Inc.	09/06/2002		
		WO 03/009847		Amgem, Inc.	02/06/2003		
BN		WO 02/067869		Merck & Co., Inc.	09/06/2002		
Examine Signatur		M	4	Date Considered	10/1/67		

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 60?. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO		COMPLETE IF KNOWN			
	INFORMATIO		LOSURE	Application Number	10/560,290
			LICANT	Filing Date	December 12, 2005
	STATEMENT I	BY APP	LICANI	First Named Inventor	H. Sings et al.
				Group Art Unit	
	(use as many sho	eets as nec	cessary)	Examiner Name	
Sheet	2	of	3	Attorney Docket Number	21278P

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
BUL	AA	Kopelman, Nature, Vol. 404 (2000), pp. 635-643, "Obesity as a medical problem"
	ΑВ	Huszar et al., Cell, Vol. 88 (1997), pp. 131-141, "Targeted disruption of the melanocortin-4 receptor results in obesity in mice"
	AC	Kask et al., Biochem. & Biophys. Res. Comm., Vol. 245 (1998), pp. 90-93, "Selected antagonist for the melanocortin 4 receptor (HSO014) increases food intake in free-feeding rats"
	AD	Chen et al., Cell, Vol. 91 (1997), pp. 789-798, "Exocrine gland dysfunction in MC5-R-deficient mice"
	AE	Giraudo et al., Brain Res., Vol. 809 (1998), pp. 302-306, "Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands"
	AF	Hill et al. Science, Vol. 280 (1998), pp. 1371-1374, "Environmental contributions to the obesity epidemic"
	AG	Corcos et al., Society for Neuroscience Abstracts, Vol. 23 (1997), Abstract No. 267.9, p. 673, "HP 228 is a potent agonist of melanocortin receptor 4, and significantly attenuates obesity and diabetes in Zucker fatty rats"
	ΑН	Peptides: Frontiers of Peptide Science, Proceedings of the 15th American Peptide Symposium, June 14-19, 1997, Nashville, TN
	AI	Wessels et al., J. of Urology, Vol. 160 (1998), pp. 389-393, "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction"
	AJ	Dorr et al., Life Sciences, Vol. 58, No. 20 (1996), pp. 1777-1784, "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study"
	AK	Wessells et al., Urology, Vol. 56 (2000), pp. 641-646, "Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction"
	AL	Graul, Drugs News & Perspectives, Vol. 9 (1996), pp. 572-575, "Latest findings on the diagnosis and treatment of erectile dysfunction"
	AM	Dinsmore et al., Brit. Med. J., Vol. 318 (1999), pp. 387-390, "ABC of sexual health erectile dysfunction"
	AN	Gingell et al., Exp. Opin. Ther. Patents, Vol. 9 (1999), pp. 1689-1696, "Emerging pharmacological therapies for erectile dysfunction"
PM	AO	Yoram et al., Current Opinion in Urology, Vol. 7 (1997), pp. 349-353, "Oral pharmacotherapy in erectile dysfunction"

		1 /
Examiner Signature	Date Considered	10/107

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Forther), Merck & Co., Inc., -7/12/2005

Si	ubstitute for form 1449B/PTO	•		COMPLETE IF KNOWN			
I	NFORMATION 1	DISC	LOSURE	Application Number	10/560,290		
	OF A OFFICE AND RIGHT TO SE	' A DD		Filing Date	December 12, 2005		
્	TATEMENT BY	APP.	LICANI	First Named Inventor	H. Sings et al.		
			,	Group Art Unit			
	(use as many sheets	as nec	essary)	Examiner Name			
Sheet 3 of 3		Attorney Docket Number	21278P				

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
MI	AP 	Heaton et al., Int'l J. of Impotence Res., Vol. 9 (1997), pp. 115-121, "A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative"					
	AQ	Budhu et al., Database Caplus on STN No. 130:223167 (1999), "Preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity"					
BUL	AR	Goulet et al., Database Caplus on STN No. 137:216872 (2002), "Acylated piperidine derivatives, specifically 1-[(aminocycloalkyl)carbonyl]piperidines, as melanocortin-4 receptor agonists, and their pharmaceutical"					
	-						
·							
ابي		<u> </u>					

Examiner Signature	Date Considered	101	(/0)

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.